Kyverna Therapeutics Inc (KYTX)

Mar 09, 2026

KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView

Mar 09, 2026

Mar 07, 2026

How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir

Mar 07, 2026

Mar 07, 2026

Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn

Mar 07, 2026

Mar 06, 2026

Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia

Mar 06, 2026

Mar 06, 2026

Kyverna secures up to $150M loan facility from Oxford Finance - MSN

Mar 06, 2026

Mar 06, 2026

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - Sahm

Mar 06, 2026

Mar 05, 2026

Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative

Mar 05, 2026

Mar 05, 2026

New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan

Mar 05, 2026

Mar 04, 2026

Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn

Mar 04, 2026

Mar 04, 2026

Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan

Mar 04, 2026

Mar 04, 2026

Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan

Mar 04, 2026

Mar 03, 2026

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget

Mar 03, 2026

Mar 03, 2026

Biotech Kyverna lines up March talks at Leerink, Jefferies events - Stock Titan

Mar 03, 2026

Mar 03, 2026

Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha

Mar 03, 2026

Mar 01, 2026

P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru

Mar 01, 2026

Feb 28, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat

Feb 28, 2026

Feb 26, 2026

Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan

Feb 26, 2026

Feb 26, 2026

Kyverna Therapeutics (KYTX) director Emany Sravan Kumar files Form 3 - Stock Titan

Feb 26, 2026

Feb 26, 2026

Is Kyverna Therapeutics Inc. undervalued by DCF analysisMarket Volume Report & AI Powered Trade Plan Recommendations - mfd.ru

Feb 26, 2026

Feb 25, 2026

Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story - Sahm

Feb 25, 2026

Feb 24, 2026

Kyverna adds two directors as board prepares for commercial stage By Investing.com - Investing.com Canada

Feb 24, 2026

Feb 24, 2026

Beam Therapeutics Inc. announced that it expects to receive $500 million in funding - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Kyverna Therapeutics Strengthens Board With New Director Appointments - TipRanks

Feb 24, 2026

Feb 24, 2026

Kyverna Therapeutics appoints biotech leaders Sravan Emany and Andrew Miller to board of directors - marketscreener.com

Feb 24, 2026

Feb 24, 2026

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - Bitget

Feb 24, 2026

Feb 24, 2026

Biotech leaders join Kyverna Therapeutics (KYTX) board as Spiegelman exits - Stock Titan

Feb 24, 2026

Feb 24, 2026

KYTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 24, 2026

Feb 22, 2026

KYTXKyverna Therapeutics Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026

Feb 20, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 20, 2026

Feb 17, 2026

Bain Capital Life Sciences discloses 5.4% Kyverna (KYTX) ownership stake - Stock Titan

Feb 17, 2026

Feb 17, 2026

Rubin-led Northpond funds show 6.1% Kyverna (KYTX) stake in 13G/A - Stock Titan

Feb 17, 2026

Feb 16, 2026

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year - Yahoo Finance

Feb 16, 2026

Feb 15, 2026

What’s Kyverna Therapeutics Inc.’s historical returnOil Prices & Safe Investment Capital Preservation Plans - mfd.ru

Feb 15, 2026

Feb 14, 2026

Wall Street Zen Downgrades Kyverna Therapeutics (NASDAQ:KYTX) to Sell - MarketBeat

Feb 14, 2026

Feb 12, 2026

What is the Moat Score of Kyverna Therapeutics IncMarket Risk Report & Long Hold Capital Preservation Plans - baoquankhu1.vn

Feb 12, 2026

Feb 11, 2026

Does Kyverna Therapeutics Inc. outperform in volatile marketsJuly 2025 EndofMonth & Verified Entry Point Signals - mfd.ru

Feb 11, 2026

Feb 11, 2026

Profit Review: Can Kyverna Therapeutics Inc. stock outperform in 2025 bull marketPortfolio Value Report & Reliable Volume Spike Trade Alerts - mfd.ru

Feb 11, 2026

Feb 11, 2026

Kyverna Therapeutics (KYTX) CTO Mayobanex Pujols reports no share ownership on Form 3 - Stock Titan

Feb 11, 2026

Feb 10, 2026

Stock Recap: Is AIRT a defensive stockWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn

Feb 10, 2026

Feb 10, 2026

Myasthenia Gravis Market Forecast Indicates 10.4% CAGR Growth by 2034, Reports DelveInsight - Barchart.com

Feb 10, 2026

Feb 09, 2026

Aug Reactions: Can Kyverna Therapeutics Inc weather a recessionQuarterly Market Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn

Feb 09, 2026

Feb 08, 2026

Aug PostEarnings: Does Koninklijke Philips NV Depositary Receipt outperform in volatile marketsQuarterly Trade Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Feb 08, 2026

Feb 07, 2026

Income Plays: Can Kyverna Therapeutics Inc maintain sales growthJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - baoquankhu1.vn

Feb 07, 2026

Feb 04, 2026

Aug Momentum: How Kyverna Therapeutics Inc. stock performs after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru

Feb 04, 2026

Feb 03, 2026

Kyverna Therapeutics appoints Mayo Pujols as chief technology officer By Investing.com - Investing.com Nigeria

Feb 03, 2026

Feb 03, 2026

Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing - TipRanks

Feb 03, 2026

Feb 03, 2026

Kyverna Therapeutics appoints Mayo Pujols as chief technology officer - Investing.com

Feb 03, 2026

Feb 03, 2026

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - Quiver Quantitative

Feb 03, 2026

Jan 28, 2026

Fund Flows: Is Kyverna Therapeutics Inc stock trending bullishEarnings Trend Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Jan 28, 2026

Jan 28, 2026

Valuation Update: Is Scully Royalty Ltd on track to beat earningsGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Jan 28, 2026

Jan 28, 2026

Street Watch: Can Kyverna Therapeutics Inc weather a recessionSell Signal & Safe Entry Zone Identification - baoquankhu1.vn

Jan 28, 2026

Jan 27, 2026

Macro Review: Can Kyverna Therapeutics Inc weather a recession2025 Earnings Surprises & High Return Trade Guides - baoquankhu1.vn

Jan 27, 2026

Jan 27, 2026

KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN

Jan 27, 2026

Jan 26, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 26, 2026

Jan 25, 2026

Does Kyverna Therapeutics Inc outperform in volatile markets2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn

Jan 25, 2026

Jan 25, 2026

Volume Summary: Will Launch One Acquisition Corp benefit from AI trendsJuly 2025 Closing Moves & Weekly Sector Rotation Insights - baoquankhu1.vn

Jan 25, 2026

Jan 23, 2026

Risk Report: Will Kyverna Therapeutics Inc outperform tech stocksTrade Analysis Summary & Community Verified Trade Signals - baoquankhu1.vn

Jan 23, 2026

Jan 20, 2026

What momentum indicators show for Kyverna Therapeutics Inc. stockPrice Action Analysis & Follow Top Performers in the Community - bollywoodhelpline.com

Jan 20, 2026

Jan 19, 2026

Will Kyverna Therapeutics Inc. stock see PE expansionWeekly Investment Report & Capital Efficiency Focused Strategies - bollywoodhelpline.com

Jan 19, 2026